Altered mRNA expression related to the apoptotic effect of three xanthones on human melanoma SK-MEL-28 Cell Line

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Wang, Jing J ^a,b   Zhang, Wei ^a,b   Sanderson, Barbara J S ^a  

^a FLINDERS UNIVERSITY   (Australia)

^b FLINDERS UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

8 DEOXYGARTANIN; ALPHA MANGOSTIN; B RAF KINASE; CASPASE 8; CASPASE 9; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYTOCHROME C; GAMMA MANGOSTIN; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PROTEIN BAX; PROTEIN BCL 2; UNCLASSIFIED DRUG; XANTHONE DERIVATIVE; AKT1 PROTEIN, HUMAN; CASP8 PROTEIN, HUMAN; CASP9 PROTEIN, HUMAN; CCND1 PROTEIN, HUMAN; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; I KAPPA B KINASE; MANGOSTIN; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; RNA;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOSOL; DOWN REGULATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; MELANOMA CELL; MITOCHONDRION; PROTEIN EXPRESSION; PROTEIN SECRETION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL; UPREGULATION; BIOSYNTHESIS; DRUG EFFECT; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION REGULATION; MELANOMA; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

APOPTOSIS; CASPASE 8; CASPASE 9; CELL LINE, TUMOR; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; G1 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; I-KAPPA B KINASE; MELANOMA; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RNA, MESSENGER; RNA, NEOPLASM; UP-REGULATION; XANTHONES;

EID: 84885660382     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/715603     Document Type: Article

References (54)

1. Gupta S., Mukhtar H., Chemoprevention of skin cancer through natural agents. Skin Pharmacology and Applied Skin Physiology 2001 14 6 373 385 2-s2.0-0035743141 10.1159/000056371 (Pubitemid 34701809)
2. Nouri K., Skin Cancer 2008 New York, NY, USA McGraw-Hill Medical
3. Orouji A., Goerdt S., Utikal J., Systemic therapy of non-resectable metastatic melanoma. Cancers 2010 2 2 955 969 2-s2.0-79952269662 10.3390/cancers2020955
4. Akao Y., Nakagawa Y., Iinuma M., Nozawa Y., Anti-cancer effects of xanthones from pericarps of mangosteen. International Journal of Molecular Sciences 2008 9 3 355 370 2-s2.0-41649101808 10.3390/ijms9030355 (Pubitemid 351482120)
5. Jung H. A., Su B. N., Keller W. J., Mehta R. G., Kinghorn A. D., Antioxidant xanthones from the pericarp of Garcinia mangostana (Mangosteen). Journal of Agricultural and Food Chemistry 2006 54 6 2077 2082 2-s2.0-33645765822 10.1021/jf052649z
6. Pedraza-Chaverri J., Cárdenas-Rodríguez N., Orozco-Ibarra M., Pérez-Rojas J. M., Medicinal properties of mangosteen (Garcinia mangostana). Food and Chemical Toxicology 2008 46 10 3227 3239 2-s2.0-52949137354 10.1016/j.fct.2008.07.024
7. Shan T., Ma Q., Guo K., Liu J., Li W., Wang F., Wu E., Xanthones from mangosteen extracts as natural chemopreventive agents: potential anticancer drugs. Current Molecular Medicine 2011 11 8 666 677 2-s2.0-80053999477 10.2174/156652411797536679
8. Wang J. J., Shi Q. H., Zhang W., Sanderson B. J., Anti-skin cancer properties of phenolic-rich extract from the pericarp of mangosteen (Garcinia mangostana Linn.). Food and Chemical Toxicology 2012 50 9 3004 3013 10.1016/j.fct.2012.06.003
9. Wang J. J., Sanderson B. J. S., Zhang W., Cytotoxic effect of xanthones from pericarp of the tropical fruit mangosteen (Garcinia mangostana Linn.) on human melanoma cells. Food and Chemical Toxicology 2011 49 9 2385 2391 2-s2.0-79960839037 10.1016/j.fct.2011.06.051
10. Datta S. R., Dudek H., Xu T., Masters S., Fu H., Gotoh Y., Greenberg M. E., Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997 91 2 231 241 2-s2.0-0030702123 10.1016/S0092-8674(00) 80405-5 (Pubitemid 27456390)
11. Cardone M. H., Roy N., Stennicke H. R., Salvesen G. S., Franke T. F., Stanbridge E., Frisch S., Reed J. C., Regulation of cell death protease caspase-9 by phosphorylation. Science 1998 282 5392 1318 1321 2-s2.0-0032515027 (Pubitemid 28524494)
12. Gardai S. J., Hildeman D. A., Frankel S. K., Whitlock B. B., Frasch S. C., Borregaard N., Marrack P., Bratton D. L., Henson P. M., Phosphorylation of Bax ser184 by Akt regulates its activity and apoptosis in neutrophils. The Journal of Biological Chemistry 2004 279 20 21085 21095 2-s2.0-2442681877 10.1074/jbc.M400063200 (Pubitemid 38656511)
13. Manning B. D., Cantley L. C., AKT/PKB signaling: navigating downstream. Cell 2007 129 7 1261 1274 2-s2.0-34250788809 10.1016/j.cell.2007.06.009 (Pubitemid 46962095)
14. Easton J. B., Houghton P. J., mTOR and cancer therapy. Oncogene 2006 25 48 6436 6446 2-s2.0-33750072949 10.1038/sj.onc.1209886 (Pubitemid 44582287)
15. Guertin D. A., Sabatini D. M., Defining the role of mTOR in cancer. Cancer Cell 2007 12 1 9 22 2-s2.0-34347220473 10.1016/j.ccr.2007.05.008 (Pubitemid 47001784)
16. Ravi R., Bedi A., NF- B in cancer-a friend turned foe. Drug Resistance Updates 2004 7 1 53 67 2-s2.0-1842607516 10.1016/j.drup.2004.01.003 (Pubitemid 38453836)
17. Seo K. H., Ko H. M., Kim H. A., Choi J. H., Park S. J., Kim K. J., Lee H. K., Im S. Y., Platelet-activating factor induces up-regulation of antiapoptotic factors in a melanoma cell line through nuclear factor- B activation. Cancer Research 2006 66 9 4681 4686 2-s2.0-33646392184 10.1158/0008-5472.CAN-05-3186
18. Munshi A., Kurland J. F., Nishikawa T., Chiao P. J., Andreeff M., Meyn R. E., Inhibition of constitutively activated nuclear factor- B radiosensitizers human cells. Molecular Cancer Therapeutics 2004 3 8 985 992 2-s2.0-4444300254 (Pubitemid 39199593)
19. Romano M. F., Avellino R., Petrella A., Bisogni R., Romano S., Venuta S., Rapamycin inhibits doxorubicin-induced NF- B/Rel nuclear activity and enhances the apoptosis of melanoma cells. European Journal of Cancer 2004 40 18 2829 2836 2-s2.0-9644252848 10.1016/j.ejca.2004.08.017 (Pubitemid 39574738)
20. Eberle J., Kurbanov B. M., Hossini A. M., Trefzer U., Fecker L. F., Overcoming apoptosis deficiency of melanoma-Hope for new therapeutic approaches. Drug Resistance Updates 2007 10 6 218 234 2-s2.0-38549111246 10.1016/j.drup.2007.09.001 (Pubitemid 351163147)
21. Mantena S. K., Sharma S. D., Katiyar S. K., Berberine inhibits growth, induces G1 arrest and apoptosis in human epidermoid carcinoma A431 cells by regulating Cdki-Cdk-cyclin cascade, disruption of mitochondrial membrane potential and cleavage of caspase 3 and PARP. Carcinogenesis 2006 27 10 2018 2027 2-s2.0-33748924524 10.1093/carcin/bgl043 (Pubitemid 44530576)
22. Soengas M. S., Capodieci P., Polsky D., Mora J., Esteller M., Opitz-Araya X., McCombie R., Herman J. G., Gerald W. L., Lazebnik Y. A., Cordón-Cardó C., Lowe S. W., Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 2001 409 6817 207 211 2-s2.0-0035843169 10.1038/35051606 (Pubitemid 32144287)
23. Johnson J. J., Petiwala S. M., Syed D. N., Rasmussen J. T., Adhami V. M., Siddiqui I. A., Kohl A. M., Mukhtar H., α -mangostin, a xanthone from mangosteen fruit, promotes cell cycle arrest in prostate cancer and decreases xenograft tumor growth. Carcinogenesis 2012 33 2 413 419 2-s2.0-84856569262 10.1093/carcin/bgr291
24. Müller M., Schleithoff E. S., Stremmel W., Melino G., Krammer P. H., Schilling T., One, two, three-p53, p63, p73 and chemosensitivity. Drug Resistance Updates 2006 9 6 288 306 2-s2.0-33847390640 10.1016/j.drup.2007.01. 001 (Pubitemid 46349815)
25. Yu Q., Restoring p53-mediated apoptosis in cancer cells: new opportunities for cancer therapy. Drug Resistance Updates 2006 9 1-2 19 25 2-s2.0-33745244111 10.1016/j.drup.2006.03.001 (Pubitemid 43928803)
26. Selzer E., Schlagbauer-Wadl H., Okamoto I., Pehamberger H., Pötter R., Jansen B., Expression of Bcl-2 family members in human melanocytes, in melanoma metastases and in melanoma cell lines. Melanoma Research 1998 8 3 197 203 2-s2.0-0031838967 10.1097/00008390-199806000-00001 (Pubitemid 28313756)
27. Hossini A. M., Eberle J., Fecker L. F., Orfanos C. E., Geilen C. C., Conditional expression of exogenous Bcl-XS triggers apoptosis in human melanoma cells in vitro and delays growth of melanoma xenografts. FEBS Letters 2003 553 3 250 256 2-s2.0-0142138711 10.1016/S0014-5793(03)01017-2 (Pubitemid 37315613)
28. Wolter K. G., Verhaegen M., Fernández Y., Nikolovska-Coleska Z., Riblett M., Martin de la Vega C., Wang S., Soengas M. S., Therapeutic window for melanoma treatment provided by selective effects of the proteasome on Bcl-2 proteins. Cell Death and Differentiation 2007 14 9 1605 1616 2-s2.0-34548011015 10.1038/sj.cdd.4402163 (Pubitemid 47278846)
29. Raisova M., Bektas M., Wieder T., Daniel P., Eberle J., Orfanos C. E., Geilen C. C., Resistance to CD95/Fas-induced and ceramide-mediated apoptosis of human melanoma cells is caused by a defective mitochondrial cytochrome c release. FEBS Letters 2000 473 1 27 32 2-s2.0-0034604053 10.1016/S0014-5793(00) 01491-5 (Pubitemid 30235179)
30. Ivanov V. N., Bhoumik A., Ronai Z., Death receptors and melanoma resistance to apoptosis. Oncogene 2003 22 20 3152 3161 2-s2.0-0038456210 10.1038/sj.onc.1206456 (Pubitemid 36713767)
31. Fulda S., Debatin K. M., Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006 25 34 4798 4811 2-s2.0-33746886979 10.1038/sj.onc.1209608 (Pubitemid 44187627)
32. Elmore S., Apoptosis: a review of programmed cell death. Toxicologic Pathology 2007 35 4 495 516 2-s2.0-34250308322 10.1080/01926230701320337 (Pubitemid 46911891)
33. Ashkenazi A., Dixit V. M., Death receptors: signaling and modulation. Science 1998 281 5381 1305 1308 2-s2.0-0032575714 (Pubitemid 28406815)
34. Green D. R., Amarante-Mendes G. P., The point of no return: mitochondria, caspases, and the commitment to cell death. Results and Problems in Cell Differentiation 1998 24 45 61 2-s2.0-0032234902
35. Krajarng A., Nakamura Y., Suksamrarn S., Watanapokasin R., α -mangostin induces apoptosis in human chondrosarcoma cells through downregulation of ERK/JNK and Akt signaling pathway. Journal of Agricultural and Food Chemistry 2011 59 10 5746 5754 2-s2.0-79957964309 10.1021/jf200620n
36. Matsumoto K., Akao Y., Yi H., Ohguchi K., Ito T., Tanaka T., Kobayashi E., Iinuma M., Nozawa Y., Preferential target is mitochondria in α -mangostin-induced apoptosis in human leukemia HL60 cells. Bioorganic and Medicinal Chemistry 2004 12 22 5799 5806 2-s2.0-6344279799 10.1016/j.bmc.2004. 08.034 (Pubitemid 39388179)
37. Matsumoto K., Akao Y., Ohguchi K., Ito T., Tanaka T., Iinuma M., Nozawa Y., Xanthones induce cell-cycle arrest and apoptosis in human colon cancer DLD-1 cells. Bioorganic and Medicinal Chemistry 2005 13 21 6064 6069 2-s2.0-25844498582 10.1016/j.bmc.2005.06.065 (Pubitemid 41399917)
38. Zou H., Henzel W. J., Liu X., Lutschg A., Wang X., Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell 1997 90 3 405 413 2-s2.0-0030745646 10.1016/S0092-8674(00)80501-2 (Pubitemid 27347231)
39. Rodriguez J., Lazebnik Y., Caspase-9 and APAF-1 form an active holoenzyme. Genes and Development 1999 13 24 3179 3184 2-s2.0-0033573020 10.1101/gad.13.24.3179 (Pubitemid 30030439)
40. Chandra D., Liu J., Tang D. G., Early mitochondrial activation and cytochrome c up-regulation during apoptosis. The Journal of Biological Chemistry 2002 277 52 50842 50854 2-s2.0-0037184954 10.1074/jbc.M207622200 (Pubitemid 36042250)
41. Adams J. M., Cory S., The Bcl-2 protein family: arbiters of cell survival. Science 1998 281 5381 1322 1326 2-s2.0-0032575688 (Pubitemid 28406819)
42. Antonsson B., Martinou J. C., The Bcl-2 protein family. Experimental Cell Research 2000 256 1 50 57 2-s2.0-0034630155 10.1006/excr.2000.4839 (Pubitemid 30211166)
43. Huang D. C. S., Strasser A., BH3-only proteins-essential initiators of apoptotic cell death. Cell 2000 103 6 839 842 2-s2.0-0033635733
44. Testa J. R., Bellacosa A., AKT plays a central role in tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America 2001 98 20 10983 10985 2-s2.0-0035949699 10.1073/pnas.211430998 (Pubitemid 32928669)
45. Alessi D. R., Andjelkovic M., Caudwell B., Cron P., Morrice N., Cohen P., Hemmings B. A., Mechanism of activation of protein kinase B by insulin and IGF-1. The EMBO Journal 1996 15 23 6541 6551 2-s2.0-0029804116 (Pubitemid 26413787)
46. Shibata M. A., Iinuma M., Morimoto J., Kurose H., Akamatsu K., Okuno Y., Akao Y., Otsuki Y., α -mangostin extracted from the pericarp of the mangosteen (Garcinia mangostana Linn) reduces tumor growth and lymph node metastasis in an immunocompetent xenograft model of metastatic mammary cancer carrying a p53 mutation. BMC Medicine 2011 9, article 69 2-s2.0-79957877575 10.1186/1741-7015-9-69
47. Han A. R., Kim J. A., Lantvit D. D., Kardono L. B. S., Riswan S., Chai H., de Blanco E. J. C., Farnsworth N. R., Swanson S. M., Kinghorn A. D., Cytotoxic xanthone constituents of the stem bark of Garcinia mangostana (mangosteen). Journal of Natural Products 2009 72 11 2028 2031 2-s2.0-73349098430 10.1021/np900517h
48. Gorden A., Osman I., Gai W., He D., Huang W., Davidson A., Houghton A. N., Busam K., Polsky D., Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. Cancer Research 2003 63 14 3955 3957 2-s2.0-0042173193 (Pubitemid 36917911)
49. Davies H., Bignell G. R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M. J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B. A., Cooper C., Shipley J., Hargrave D., Pritchard-Jones K., Maitland N., Chenevix-Trench G., Riggins G. J., Bigner D. D., Palmleri G., Cossu A., Flanagan A., Nicholson A., Ho J. W. C., Leung S. Y., Yuen S. T., Weber B. L., Seigler H. F., Darrow T. L., Paterson H., Marais R., Marshall C. J., Wooster R., Stratton M. R., Futreal P. A., Mutations of the BRAF gene in human cancer. Nature 2002 417 6892 949 954 2-s2.0-18444374405 10.1038/nature00766 (Pubitemid 34716871)
50. Kumar R., Angelini S., Czene K., Sauroja I., Hahka-Kemppinen M., Pyrhönen S., Hemminki K., BRAF mutations in metastatic melanoma: a possible association with clinical outcome. Clinical Cancer Research 2003 9 9 3362 3368 2-s2.0-0041333110 (Pubitemid 37082731)
51. Yang H., Higgins B., Kolinsky K., Packman K., Go Z., Iyer R., Kolis S., Zhao S., Lee R., Grippo J. F., Schostack K., Simcox M. E., Heimbrook D., Bollag G., Su F., RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Research 2010 70 13 5518 5527 2-s2.0-77954376912 10.1158/0008-5472.CAN-10-0646
52. Joseph E. W., Pratilas C. A., Poulikakos P. I., Tadi M., Wang W., Taylor B. S., Halilovic E., Persaud Y., Xing F., Viale A., Tsai J., Chapman P. B., Bollag G., Solit D. B., Rosen N., The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proceedings of the National Academy of Sciences of the United States of America 2010 107 33 14903 14908 2-s2.0-77957089182 10.1073/pnas.1008990107
53. Hong D. S., Vence L., Falchook G., Radvanyi L. G., Liu C., Goodman V., Legos J. J., Blackman S., Scarmadio A., Kurzrock R., Lizee G., Hwu P., BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency. Clinical Cancer Research 2012 18 8 2326 2335 2-s2.0-84859807701 10.1158/1078-0432.CCR-11-2515
54. Nakagawa Y., Iinuma M., Naoe T., Nozawa Y., Akao Y., Characterized mechanism of α -mangostin-induced cell death: caspase-independent apoptosis with release of endonuclease-G from mitochondria and increased miR-143 expression in human colorectal cancer DLD-1 cells. Bioorganic and Medicinal Chemistry 2007 15 16 5620 5628 2-s2.0-34250705898 10.1016/j.bmc.2007.04.071 (Pubitemid 46962985)